January 15, 2009
Marquette Magazine - By Nicole Sweeney Etter
February 26, 2010
MedCity News - By Brandon Glenn
August 24, 2012
Promentis Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting compounds that show promise as neuroprotective agents for patients suffering from Parkinson’s disease.
August 24, 2012
Milwaukee Journal Sentinel - By Kathleen Gallagher
September 25, 2012
Promentis Pharmaceuticals, Inc. announced today that it has received a Phase II Small Business Innovation Research (SBIR) award from the National Institute of Mental Health (NlMH) of the National Institutes of Health. The three-year award, totaling $1.8 million, is the continuation of a Phase I SBIR grant received previously by Promentis to develop novel compounds to treat schizophrenia.
September 25, 2012
Milwaukee Journal Sentinel - By Kathleen Gallagher
August 7, 2013
Milwaukee Business Journal – By Jeff Engel
January 16, 2014
Milwaukee Journal Sentinel - By Kathleen Gallagher
January 16, 2014
Milwaukee Business Journal - By Rich Kirchen
January 21, 2014
Promentis Pharmaceuticals, Inc., a specialty pharmaceutical company developing novel compounds for schizophrenia, Parkinson's disease and pediatric disorders including autism, announced today it has raised nearly $3 million in Series B financing.
January 22, 2014
January 27, 2014
BioCentury Week in Review
February 12, 2015
Xconomy - By Jeff Engel
October 16, 2015
Xconomy - By Jeff Buchanan
January 27, 2016
Milwaukee Magazine - By Claire Hanan
March 30, 2017
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders, today announced it has completed a third round of equity investment totaling $26,000,000.
November 20, 2017
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023.
October 29, 2018
Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California.
November 16, 2018
Promentis plans to initiate monotherapy and add-on therapy studies in two neuropsychiatric disorders Milwaukee, Wisconsin | November 16, 2018 — Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical […]
December 5, 2018
Dr. Chad Beyer to provide nonclinical and clinical findings of the company’s first-in-class, System xc– activator Milwaukee, WI – December 5, 2018 — Promentis Pharmaceuticals, Inc., a […]